Fundraising Fox
Bluewhale
Philadelphia, US · Founded 2022 · Delaware corporation · 17 known investors
Find your way into Bluewhale
Sign up to see every warm intro you have to Bluewhale
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bluewhale team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BlueWhale Bio develops manufacturing technologies for cell-based therapies, focusing on cell activation and expansion in early-stage processing to improve efficiency and reduce costs. The company serves medical institutions and therapeutics developers working with cell therapy products.
Founders & leadership
Board
Investors · 17
How we know: Ascendo Ventures's portfolio page · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: thesaasnews.com · Not right? Tell us
How we know: thesaasnews.com · Not right? Tell us
How we know: thesaasnews.com · Not right? Tell us
How we know: thesaasnews.com · Not right? Tell us
Also in the syndicate · 8
Funding
SEC filings, press & company announcements$5M disclosed across 1 of 2 rounds · 2024–2025
- Undisclosed amountseed fundingMar 2024
SBI (lead), SBI Decima (lead), SBI Ven Capital (lead), Animoca, Azimut, Baselayer Capital, Cardano, Ghaf Capital Partners, Gumi, Momentum6, MZ Crypto, NxGen, Primal Capital, Spyre Capital, Sygnum
Source ↗
▶$5MraisedOct 2025 · 1 investors · BiotechnologyRule 506(b)
- Elaine HeronDirector
- Peter KellerExecutive Officer, Director
- Paul MeisterDirector
- Paula CannonDirector
- Beate Mueller-TiemannDirector
- Offering amount
- $15M
- Amount sold
- $5M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
▸Research sources · 5
primary sources listed
- Blue Whale Acquisition Corp I Announces Closing of $200,000,000 Initial Public Offeringprnewswire.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Bluewhale do?
- BlueWhale Bio develops manufacturing technologies for cell-based therapies, focusing on cell activation and expansion in early-stage processing to improve efficiency and reduce costs. The company serves medical institutions and therapeutics developers working with cell therapy products.
- Who are Bluewhale's investors?
- Bluewhale's investors include Ascendo Ventures, Novalis LifeSciences, Baselayer Capital, Cardano, Ghaf Capital Partners, gumi Inc, PRIMAL CAPITAL, SBI Ven Capital and 1 more.
- How much funding has Bluewhale raised?
- Bluewhale has disclosed $5M raised across 1 of its 2 known rounds.
- Where is Bluewhale headquartered?
- Bluewhale is headquartered in Philadelphia, US.